Transaction Expected to Close in February 2025GRANT-VALKARIA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL), a Delaware corporation (“Kaival” or the “Company”) and the U.S. distributor of the Bidi® Stick and certain other products manufactured by Bidi Vapor, LLC (“Bidi Vapor”), and Delta Corp Holdings Limited, a company incorporated in England and Wales (“Delta”) and a privately held holding company for global businesses engaged in Bulk & Energy logistics, fuel ...

Company Leadership - Terranet has appointed Lars Lindell as the new CEO, effective no later than April 10, 2025 [1] - Lars Lindell brings over 30 years of international experience in leading fast-growing tech companies, including roles in the automotive and telecom sectors [1] - He previously served as CEO of Acconeer AB for 10 years [1] - Terranet's Chairman of the Board, Torgny Hellström, highlights Lars Lindell's extensive experience in driving growth and profitability in technology-driven companies, both in Sweden and internationally [1] - Lars Lindell is recognized for his vast international network, leadership skills, and proven ability to deliver strong results [1] - During the interim period, Terranet's CFO, Dan Wahrenberg, will serve as acting CEO [1] CEO's Vision and Strategy - Lars Lindell emphasizes the significant changes in the world, particularly the development toward fully autonomous vehicles, which demand better sensor technology [2] - He expresses optimism and a sense of responsibility as the new CEO, given Terranet's cutting-edge technology with the potential to save countless lives in traffic annually [2] - Lars Lindell aims to commercialize Terranet's technology, positioning Sweden as a leader in safety innovation [2] Company Overview - Terranet is headquartered in Lund, with offices in Gothenburg and Stuttgart [4] - The company has been listed on Nasdaq First North Premier Growth Market since 2017 (Nasdaq: TERRNT-B) [4] - Terranet's mission is to save lives in urban traffic by developing innovative technical solutions for Advanced Driver Assistance Systems (ADAS) and Autonomous Vehicles (AV) [5] - The company's anti-collision system, BlincVision, laser scans and detects road objects up to ten times faster than any other ADAS technology available today [5] Industry Context - The automotive industry is undergoing significant changes, with a focus on fully autonomous vehicles and the need for advanced sensor technology [2] - Terranet's technology is positioned to address these industry demands, particularly in enhancing safety and reducing traffic-related fatalities [2][5]

CHARLOTTE, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Coca‑Cola Consolidated, Inc. (NASDAQ:COKE) announced today that Executive Vice President and Chief Financial Officer (CFO), Scott Anthony, will retire effective March 31, 2025. Mr. Anthony has served as the Company's CFO since 2018. The Company also announced that Matthew J. Blickley will assume the role of Executive Vice President and Chief Financial Officer, effective April 1, 2025. Mr. Blickey joined Coca‑Cola Consolidated in 2014 and currently serves as ...

Reports preliminary fourth quarter 2024 revenue in the range of approximately $19.2 million to $19.4 millionReports preliminary full-year 2024 revenue in the range of approximately $73.1 million to $73.3 millionIradimed is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15th, 2025, at 5:15 p.m. PT  WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD), a leader in developing innovative Magnetic Resonance ...

First Quarter Fiscal 2025 Revenue Includes a One-Time Upfront Payment of $3.0 Million in Collaboration Revenue from Zimmer Biomet and $3.2M in Product Revenue Management to Host Virtual Investor Webinar Today at 11:00 a.m. Eastern Time EDEN PRAIRIE, Minn., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorder ...

FREDERICK, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® ("TOMI") (NASDAQ:TOMZ), a global company specializing in disinfection and decontamination solutions, today announced that the Company is supporting partners and clients preparing for emerging public health threats as concerns grow over Respiratory Syncytial Virus (RSV), Human Metapneumovirus (HMPV), and the highly pathogenic Avian Influenza (H5N1). TOMI is leveraging its SteraMist technology to provide innovative infection ...

BOSTON, Jan. 10, 2025 /PRNewswire/ -- The Berkshire Hills Bancorp, Inc. (NYSE: BHLB) fourth quarter 2024 earnings release and conference call are scheduled as follows: Earnings Release:      Thursday, January 30, 2025, at approximately 7:30 a.m. (Eastern) Conference Call:        Thursday, January 30, 2025, at 9:00 a.m. (Eastern) Webcast (listen-only):  Register at: https://events.q4inc.com/attendee/539841607 Dial-in Number:          Toll Free: (800) 715-9871; Conference ID 6567963 Webcast Replay:         ht ...

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it priced its public offering of 5,000,000 shares of common stock at a price of $0.85 per share.   The closing of the offering is expected to occur on or about January 10, 2025, subject to satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as ex ...

Partnership Agreement - Samsung Bioepis and Teva Pharmaceutical Industries have entered into a license, development, and commercialization agreement for EPYSQLI®, a biosimilar to Soliris®, in the US [1] - Samsung Bioepis will handle development, regulatory registration, manufacturing, and supply, while Teva will manage commercialization in the US [2] - EPYSQLI is indicated for treating rare diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG) [3] Strategic Importance - The partnership aims to increase access to treatment for rare disease patients, addressing high costs and limited availability [4] - The collaboration aligns with Teva's Pivot to Growth strategy, expanding its biosimilar portfolio to 18 assets [5] - Samsung Bioepis' biosimilars portfolio now includes nine biosimilars available in over 40 countries, covering therapeutic areas such as immunology, oncology, and hematology [5] Regulatory Approvals - EPYSQLI was approved by the US FDA in July 2024 for PNH and aHUS, with an expanded indication for gMG in November 2024 [4] - The product received approval from the European Commission in May 2023 and Korea's Ministry of Food and Drug Safety in January 2024 [4] - EPYSQLI has been commercially available in Europe since July 2023 and in Korea since April 2024 [4] Product Details - EPYSQLI is a complement inhibitor used to treat PNH, aHUS, and gMG in adult patients who are anti-acetylcholine receptor (AchR) antibody positive [3][6] - The product is not indicated for Shiga toxin E coli-related hemolytic uremic syndrome (STEC-HUS) [8] - EPYSQLI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) due to the risk of serious meningococcal infections [10][17] Safety Information - EPYSQLI increases the risk of serious infections caused by Neisseria meningitidis, which can be life-threatening or fatal [9][12] - Patients must complete or update meningococcal vaccination at least two weeks prior to the first dose of EPYSQLI [13][15] - Monitoring for early signs of meningococcal infection is critical, and treatment should be interrupted if serious infection occurs [16] Adverse Reactions - Common adverse reactions in PNH trials include headache, nasopharyngitis, back pain, and nausea [27] - In aHUS trials, frequent adverse reactions include headache, diarrhea, hypertension, and upper respiratory infection [27] - In gMG trials, musculoskeletal pain was the most frequently reported adverse reaction [28]

Singapore, Jan. 10, 2025 (GLOBE NEWSWIRE) -- SIMPPLE Ltd. (NASDAQ:SPPL) ("SIMPPLE" or "the Company"), a leading technology provider and innovator in the facilities management (FM) sector, today announced that Norman Schroeder, the Company's Chief Executive Officer, has issued the following Letter to Shareholders. Dear Shareholders: As we reflect and assess the year that has been, I would like to thank you for your continued confidence, and support throughout 2024, a transformative year of growth, delivering ...